OneSource Specialty Pharma Reports 37% Revenue Growth and 39% EBITDA Growth in Q1 FY27; Reaffirms FY28 Guidance

What Happened ?

Key details

Financial Performance:

The company reported broad-based improvement across key financial metrics.

• Revenue increased 37% YoY to ₹449 crore.
• EBITDA rose 39% YoY to ₹123.3 crore.
• EBITDA margin expanded to 27.5% due to improved operating leverage.
• Adjusted PAT increased 72% YoY to ₹63.7 crore.
• Revenue growth was supported by semaglutide commercialisation, new MSA contracts and customer additions.

Commercial Momentum:

Business development remained strong during the quarter.

Key achievements included:

• 11 new customer wins.
• 6 new customer logos, taking the customer base to 80+.
• 9 new product launches across customers and modalities.
• More than 70 active RFPs in the pipeline.
• Four-fold growth in the RFP funnel compared with FY25. 

GLP-1 Leadership:

OneSource continued strengthening its position in the rapidly growing GLP-1 market.

Highlights include:

• First and only CDMO with three G7 semaglutide approvals.
• Commercial semaglutide launches in Canada and India.
• Launch planned in the Middle East & North Africa (MENA) region through Hikma.
• Two First-to-File opportunities in the US for tirzepatide secured by customers.
• More than 20 customers across the Drug Device Combination (DDC) portfolio. 

Capacity Expansion:

The company continued investing in manufacturing capacity.

Key developments:

• Second cartridge production line scheduled for commercialisation in Q2 FY27.
• Phase 1 expansion expected to double sterile production days.
• Phase 2 installation planned during FY27 to triple sterile production capacity by FY28.
• Approximately 80% of the announced US$100 million capital expenditure programme has already been committed. 

Biologics Business:

The biologics platform continued gaining momentum.

Major developments:

• Added another leading global biosimilar customer.
• Announced strategic biosimilar partnership with Formycon.
• Expanded microbial and mammalian biologics manufacturing capabilities.
• Growing opportunities across biosimilars, innovators and animal health CDMO segments.
• Strong customer engagement supported by favourable global biosimilar industry trends. 

Quality & Regulatory Performance:

Operational execution remained strong.

The company reported:

• 12 regulatory inspections and customer audits during the quarter.
• Successful receipt of EU GMP and TGA GMP approvals across two manufacturing sites.
• Continued strong compliance track record supporting global customer confidence. 

Management Commentary:

CEO & Managing Director Neeraj Sharma said FY27 has started strongly, driven by semaglutide commercialisation in Canada and India. He highlighted that the second cartridge line is expected to begin commercial operations in Q2 FY27 and noted that the biologics business continued gaining momentum with the addition of another leading global biosimilar customer, reinforcing OneSource’s integrated CDMO capabilities. 

Note:

• OneSource’s Q1 FY27 performance demonstrates strong execution across both financial and operational parameters. Revenue growth was supported by commercial scale-up in GLP-1 products, while improving operating leverage translated into higher EBITDA margins and earnings growth.
• Continued customer additions, expansion of biologics capabilities and upcoming capacity additions position the company well to pursue its reaffirmed FY28 target of US$400 million organic revenue with a 40% EBITDA margin, although successful execution of capacity expansion and sustained demand in GLP-1 therapies will remain key to achieving these objectives. 

Risk Analysis

Summary:

• While business momentum remains strong, execution of expansion projects and continued commercial success in GLP-1 therapies are critical for sustaining the company’s growth trajectory.

Key Risks:

• Delay in commissioning new cartridge production lines could impact capacity expansion.
• Growth remains significantly linked to continued demand for semaglutide and GLP-1 products.
• Regulatory approvals and compliance remain critical for global CDMO operations.
• Customer concentration in large commercial programmes could affect revenue visibility.
• Execution risks remain around scaling biologics manufacturing capacity.

Worst Case:

• Delays in capacity expansion, slower GLP-1 commercialisation or regulatory setbacks could impact revenue growth and postpone achievement of the company’s FY28 guidance.

Risk Level: Medium

Company Commentary

• Revenue increased 37% YoY to ₹449 crore.
• EBITDA grew 39% YoY, with margin improving to 27.5%.
• Adjusted PAT rose 72% YoY to ₹63.7 crore.
• Added 11 new customer wins, expanded biologics partnerships and strengthened the GLP-1 portfolio.
• Second cartridge line is expected to become operational in Q2 FY27.
• Management reaffirmed FY28 guidance of US$400 million organic revenue and 40% EBITDA margin.